EMORY UNIVERSITY;DANA-FARBER CANCER INSTITUTE, INC.
发明人:
申请号：
EP09816950.1
公开号：
EP2342226B1
申请日:
2009.09.25
申请国别(地区):
EP
年份:
2016
代理人:
摘要：
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
